Forty Seven fortyseveninc.com


Public list: Smart Money VCs (6328) Pharma Startups (4733) Cancer Therapeutics (1136) Google In Healthcare (60)

Forty Seven is a clinical-stage immuno-oncology company that is developing therapies licensed from Stanford University targeting cancer immune evasion pathways. The lead program Hu5F9-G4 is a monoclonal antibody against the CD47 receptor, a "don't eat me" signal that cancer cells commandeer to avoid being ingested by the immune system. This antibody is currently being evaluated in two Phase 1 clinical studies in patients with solid tumors and in patients with acute myeloid leukemia.

Forty Seven is a clinical-stage immuno-oncology company that is developing therapies licensed from Stanford University targeting cancer immune evasion pathways. The lead program Hu5F9-G4 is a monoclonal antibody against the CD47 receptor, a "don't ea...Show all

Company (IPO / Went public)

Phone: 650-352-4150

Fax:

1490 O'Brien Drive
Suite A
Menlo Park, 94025
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Forty Seven $267.6M Jun 28, 2018
See all 12 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Forty Seven Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 7 investors

Competitors

Company Status Description Investors
See all 12 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Disrupting fc receptor engagement on macrophages enhances efficacy of anti-sirpalpha antibody therapy Jul 26, 2017 Application